AIOBIO Co., Ltd
KKRX:4476902,000.00
KRW
+1.00
(+0.05%)
ISIN
KR7447690009
Return %
Stock
S&P 500
1Y
-43.50
14.20
3Y
-50.43
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Hong-Cheol Yun
- Full Time Employees
- 44
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Seoul South Korea
- IPO Date
- Dec 28, 2022
- Website
- aiobio.co.kr
- Similar Companies
- Business
- AIOBIO Co., Ltd. is a South Korea-based medical device and digital healthcare company specializing in the development, manufacture, and commercialization of bio-fluorescence optical diagnostic systems and software platforms for oral health assessment. The company develops non-invasive diagnostic equipment powered by Quantitative Light-induced Fluorescence (QLF) technology, which utilizes 405-nanometer visible blue light to visualize and quantify bacterial porphyrins, early-stage dental caries, micro-fractures, dental plaque, and calculus without radiation exposure. AIOBIO Co., Ltd. operates through two core segments: Dental Diagnostic Hardware and Digital Healthcare Software. Its product portfolio comprises Qraycam Pro, a flagship chairside full-mouth screening and diagnostic imaging camera for comprehensive oral cavity examinations; Qraypen C, an ergonomic, pen-type intraoral camera designed for high-resolution analysis of individual teeth, proximal surfaces, and micro-cracks; Qscan Plus, a compact handheld screening device engineered for fast visual inspections in dental clinics and preventive home-care settings; QA2, a proprietary image analysis software that evaluates QLF imagery and quantifies lesion severity; LINKDENS, a cloud-based Software-as-a-Service (SaaS) and artificial intelligence-driven platform connecting dental practitioners with patients for longitudinal oral health monitoring, risk profiling, and clinical reporting; and QBLISS, an integrated digital oral health ecosystem bridging diagnostic hardware with cloud-based preventative care workflows. The company primarily serves dental clinics, hospitals, research institutions, and academic medical centers across domestic and international markets. Founded in August 2011, AIOBIO Co., Ltd. is headquartered in Seoul, South Korea, and is publicly traded on the Korea Exchange KONEX market under the ticker symbol 447690. In recent strategic developments, the company obtained U.S. Food and Drug Administration (FDA) 510(k) Class II medical device clearance for its Qraycam Pro system in September 2024. In August 2026, AIOBIO entered into a major commercial distribution partnership with Patterson Dental to launch and distribute Qraycam Pro and its integrated software solutions across the United States. Additionally, supported by the integration of its QLF diagnostic method into South Korea's National Health Insurance reimbursement program, AIOBIO continues to accelerate the clinical rollout of its LINKDENS platform while actively advancing preparations for a transfer listing from the KONEX market to the KOSDAQ board under the lead underwriting of Korea Investment & Securities.